Showing results (211-220 of 226) with videos related to
Sort By:
Pageof 23
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 4, 2017
Long-Term Incidence of Secondary Malignancies after Allogeneic Hematopoietic Cell Transplantation: A Single-Center ExperienceFotios V Michelis, Rouslan Kotchetkov, Rebecca M Grunwald, et al.Blood|January 31, 2013
Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasmsJames A Kennedy, Eshetu G Atenafu, Hans A Messner, et al.Bone Marrow Transplantation|December 23, 2003
The role of allogeneic bone marrow transplantation in adult patients below the age of 55 years with acute lymphoblastic leukemia in first complete remission: a donor vs no donor comparisonV Gupta, Q-L Yi, J Brandwein, et al.Leukemia & Lymphoma|February 28, 2007
Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (>5 years)Bruno C Medeiros, Mark D Minden, Andre C Schuh, et al.Current Oncology (Toronto, Ont.)|December 3, 2015
Human albumin eye drops as a therapeutic option for the management of keratoconjunctivitis sicca secondary to chronic graft-versus-host disease after stem-cell allograftingJ T Seki, N Sakurai, S Moldenhauer, et al.British Journal of Haematology|May 15, 2009
Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimenJohn M Storring, Mark D Minden, Susan Kao, et al.The Journal of Prevention of Alzheimer'S Disease|December 21, 2018
Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention: What Evidence is Meaningful to Patients, Providers, and Payers?D A Messner, P Rabins, A C Downing, et al.European Journal of Haematology|July 26, 2023
Prognostic implication of pre-transplant FEV1 on long-term outcomes following allogeneic hematopoietic stem cell transplantationIgor Novitzky-Basso, Wilson Lam, Caden Chiarello, et al.Journal of the American Society of Nephrology : JASN|October 7, 2004
Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of riskDenis Cournoyer, Edwin B Toffelmire, George A Wells, et al.Bone Marrow Transplantation|March 2, 2016
Relationship between neurocognitive functioning and medication management ability over the first 6 months following allogeneic stem cell transplantationS Mayo, H A Messner, S B Rourke, et al.Pageof 23